Japan's Functional Food Regulations in 2026: FOSHU, FFC, and Why the Label Language Matters

Jun 6, 2026 10 min read

Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet, exercise, or supplement regimen.

Japan has two formal regulatory tiers for foods and supplements making health-related claims. Overseas buyers regularly encounter products carrying labels from one or both tiers — the 特定保健用食品 (Tokuho / FOSHU) designation and the 機能性表示食品 (Functional Food Claims, or FFC) system — without a clear account of what those labels require of the manufacturer or what they are warranted to say. The differences matter. They affect the evidentiary threshold behind a health claim, the government body responsible for review, and what is legally permissible on the label. Neither system maps cleanly onto FDA dietary supplement regulation or EU authorized health claims, though each shares partial structural features with both.

As of the Consumer Affairs Agency’s most recently published database figures, the FFC notification register contains over 6,000 active product notifications — a substantial increase from the roughly 210 products that appeared when the system launched in April 2015. The Ministry of Health, Labour and Welfare (MHLW) FOSHU approval registry, which operates on a separate track with individual product reviews, holds approximately 1,000 approved products as of the latest MHLW count. What distinguishes these registries, and which ingredients carry approved or notified claims in each system, is the substance of this article.

How FOSHU works

FOSHU — formally 特定保健用食品, or Food for Specified Health Uses — has operated since 1991 under MHLW authority. Unlike the FFC system, FOSHU requires individual product-level approval from MHLW before any health claim may appear on the label. That review process requires manufacturers to submit clinical trial data specific to the final product formulation — not generic ingredient evidence, but trials conducted on the specific formulation at the specific dose the product will carry to market. The review evaluates whether the evidence supports the specific claim at the claimed intake, whether the product is safe, and whether the claim language is appropriately scoped.

FOSHU claim categories span established functional domains: intestinal regulation (the largest single segment, built largely on dietary fiber and lactobacillus-based products), support for healthy blood cholesterol levels, support for healthy blood triglyceride levels, blood pressure maintenance, bone health, and blood glucose response after meals. The claim is always framed around a physiological marker or functional outcome — not a disease diagnosis. That positioning is a structural feature of the system, not incidental label language.

Because MHLW reviews each product individually, FOSHU approval is resource-intensive. The process typically requires two to five years of clinical documentation. That constraint has shaped the market: the approximately 1,000 approved products are concentrated among large food and supplement manufacturers with clinical trial infrastructure. Small producers generally cannot access the FOSHU tier, which is part of what created the policy rationale for the FFC system.

How FFC works

The Functional Food Claims system, launched in April 2015 under the Consumer Affairs Agency (消費者庁), was designed to create a lower-cost pathway for smaller manufacturers and to allow the functional food market to grow beyond the FOSHU capacity bottleneck. The mechanism differs fundamentally: FFC is a notification system, not an approval system. Manufacturers submit dossiers to the Consumer Affairs Agency’s online database (届出DB) and, after a 60-business-day review window, may begin selling under a claim if the agency raises no objections. The burden of substantiation is on the manufacturer; the government’s role is review and objection rather than active approval.

The evidentiary standard for FFC allows either a manufacturer-sponsored clinical trial conducted on the specific product or a systematic review of published research showing that the ingredient-form-dose combination is supported in the literature for the specific claim. Both routes require the evidence to directly address the claim the product intends to make. The Consumer Affairs Agency maintains the full notification database publicly at the agency’s online portal, meaning researchers and consumers can examine the submitted evidence basis for any notified product — a transparency feature with no direct equivalent in US supplement regulation.

The database has grown from roughly 210 notifications at launch to over 6,000 active notifications through 2024, with the trajectory reflecting strong industry adoption after initial uncertainty about the system’s scope. The category spread is broader than FOSHU’s: cognitive function support, sleep quality-related claims, eye strain, muscle and joint function, and post-meal blood sugar response appear in the FFC notification record alongside the intestinal regulation and cardiovascular marker claims that dominate FOSHU.

One structural feature distinguishes FFC from FOSHU that is worth noting for overseas readers: FFC products must carry a mandated disclosure stating that the Consumer Affairs Agency has not evaluated the claim, that the product is not a medicine, and that the FFC system operates on manufacturer notification. That disclosure is printed on the label of every FFC product — a transparency requirement that has no FOSHU or US supplement parallel.

Key ingredients and their claim status in 2026

Four ingredient categories appear consistently in current FOSHU and FFC discussions, each with a different evidentiary profile and claim history.

Lactobacillus strains. Lactic acid bacteria and related probiotic species represent the most numerically dense segment of both registries. FOSHU’s intestinal regulation category was built substantially on this ingredient class; multiple strains — including Lactobacillus gasseri, L. helveticus, and related species — have product-specific approvals for claims related to intestinal flora balance and regularity. FFC notifications have extended the claim landscape for specific strains into immune marker support and visceral fat-associated claims, with each notification requiring the evidence to be specific to the strain at the dose. The strain-specificity matters: a claim backed for one Lactobacillus species at a given dose is not transferable to a related species at a different dose — a distinction the notification database enforces at submission. Japanese lactobacillus probiotic supplements on Amazon covers brands with strain-specific formulations available internationally.

Lutein. Lutein and zeaxanthin claims in the FFC system are concentrated around visual function — specifically, macular carotenoid accumulation associated with contrast sensitivity and reduction in eye fatigue markers. The underlying evidence draws on a body of RCT data examining lutein supplementation and measurable visual function outcomes, including Japanese-conducted trials on digital eye fatigue indicators such as contrast sensitivity and glare recovery, and the broader international research literature on lutein and macular carotenoid status. FOSHU has also approved products combining lutein with other carotenoids for visual function-related claims, though this category is smaller in approved-product count than the intestinal regulation segment. Japanese lutein zeaxanthin eye supplements on Amazon covers the main product options available internationally.

EPA and DHA. Fish-derived omega-3 fatty acids EPA and DHA carry some of the longest-established functional food claim histories in Japan. Multiple FOSHU approvals exist for claims related to blood triglyceride management and blood pressure maintenance. The evidence base for EPA and DHA on these markers is among the more substantial in the functional food category: the Japan Public Health Center-based Prospective Study has documented associations between dietary fish consumption and cardiovascular marker outcomes within Japanese adult cohorts, and a large international RCT literature supports specific EPA/DHA dose ranges for triglyceride-related claims. Japan is also the origin of prescription-grade EPA formulations: MHLW-approved purified EPA has been prescribed for dyslipidemia management in Japan since the 1990s under a pharmaceutical approval track — a distinct regulatory category from the functional food system, though both draw on the same pharmacology. Japanese EPA DHA fish oil omega-3 supplements on Amazon covers the supplement-tier product range available internationally.

Plasmalogen. Plasmalogen is the most recently prominent ingredient in this group, and the one with the most preliminary evidence base. Plasmalogens are a subclass of phospholipids — particularly phosphatidylethanolamine plasmalogens — found in concentration in brain tissue, heart, and skeletal muscle. Japanese research groups have published studies examining the relationship between plasmalogen levels and cognitive function markers in older adults. FFC notifications for chicken-breast-derived plasmalogen products began appearing in the Consumer Affairs Agency database in the early 2020s, and the category has expanded as more manufacturers have developed products for cognitive function-related claim notifications. The evidence for plasmalogen in this context is currently described as preliminary — FFC notification submissions for plasmalogen generally draw on smaller Japanese RCT and observational data rather than the larger trial record available for EPA/DHA or lactobacillus strains. This is consistent with the FFC system’s design: the notification pathway allows earlier-stage evidence to support a claim, provided the systematic review is transparent about effect size and study limitations. Plasmalogen supplements from Japanese producers on Amazon reflects the current international availability picture for this category.

What the regulatory label means for overseas buyers

Neither FOSHU approval nor FFC notification is equivalent to a therapeutic claim. MHLW’s statutory framing and the Consumer Affairs Agency’s notification requirements both position functional food claims around physiological markers and functional outcomes — not disease treatment — and the required label disclosures reinforce that distinction. A FOSHU product carrying a claim related to blood pressure maintenance is not making the same assertion as a prescription antihypertensive, and both the Japanese regulatory structure and the mandated label language are designed to make that distinction explicit.

For overseas buyers, the practical implication is that the label language on Japanese functional foods — claim language framed around health function rather than disease outcomes — reflects a deliberate regulatory calibration. The FOSHU approval or FFC notification indicates that a government body has reviewed the submitted evidence for the specific claim, that the product passed safety evaluation, and that the claim language has been constrained to what the evidence supports at the approved or notified level. It does not indicate that any individual user will experience a specific outcome, and it does not replace advice from a healthcare professional familiar with that individual’s situation.

The Consumer Affairs Agency’s notification database (届出DB) is publicly searchable at the agency’s online portal — in Japanese, but navigable with translation tools — allowing direct review of submitted systematic reviews and trial summaries for any notified FFC product. That searchability is part of what distinguishes the Japanese system from unregulated dietary supplement markets and partly explains why Japanese functional food claims carry structural credibility even where the underlying evidence remains at an early stage.

How this connects to the supplement research cluster

The FFC and FOSHU frameworks address food-category products in Japan’s domestic market — not the full scope of the international supplement category. Ingredients like NMN, CoQ10, and astaxanthin, which carry substantial Japanese research histories and significant production infrastructure, generally fall outside the FOSHU/FFC framework as currently defined: they are sold internationally as dietary supplements without equivalent Japanese regulatory claim status in most cases. The regulatory distinction matters when evaluating what kind of label claim language is backed by what kind of evidence review.

Japanese NMN supplements: what the evidence shows covers NMN, a compound with significant Japanese clinical research investment — including trials by Yoshino et al. (2021) and Igarashi et al. (2022) — but a different regulatory context than the functional food categories described here. CoQ10 and ubiquinol: Japan’s mitochondrial aging research covers CoQ10, for which Japan has both substantial production infrastructure and a research base that predates the FFC system’s existence. Japanese astaxanthin: the evidence behind the marine carotenoid covers astaxanthin, where Japan is a principal producer and where FFC-notified products coexist alongside the broader international supplement market.

The FOSHU and FFC systems collectively represent one answer to the question of why Japanese health food carries the specific trust signals it does: not because the underlying science is uniformly stronger than elsewhere, but because the system requires a manufacturer to document their evidentiary basis, submit it to a government database, and use label language the regulator has reviewed. That structural accountability — visible at the Consumer Affairs Agency’s notification portal — is the thing worth understanding when evaluating what a Japanese functional food label is actually warranted to say.